Devatis AG was founded in 2018 in Cham, Switzerland. Behind Devatis AG is EastPharma Ltd, which was established in 2006 with the aim of becoming a major player in the pharmaceutical industry and had been listed on London Stock Exchange (LSE) between 2008 and August 2019.

Currently, the porfolio of Devatis AG consists of hematology, oncology, calcimimetics and antibiotics products and is still growing into other therapeutic areas such as cardiology and anti-fungal. 

DEVA Holding, pioneering Turkish pharmaceutical company, was founded in 1958 by group of medical doctors and pharmacists with main scope of business including manufacturing and marketing of high quality pharmaceutical finished products and active ingredients. Company has export operations to more than 60 countries worldwide.

Our Philosophy: We are committed to improving access to quality medicines.
Our Corporate Goal: Continuous growth by expanding our product portfolio to establish a strong brand.

Strong Market Presence

DEVA Holding A.Ş. was founded in 1958 by a group of doctors, pharmacists and veterinarians. Since 1986 DEVA Holding shares have been traded on Istanbul Stock Exchange. Majority shares of DEVA Holding were acquired in 2006 by the funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to take on the management.

With its main scope of business covering manufacturing and marketing of medicines for human use and raw materials, DEVA Holding also produces veterinary drugs, medical vials. Having a strong presence in the domestic market, DEVA Holding also exports finished products and raw materials to more than 60 countries worldwide.

Growing over 60 years in the Turkish pharmaceutical market, DEVA, with its broad product portfolio in different therapeutic areas, became one of the leading pharmaceutical companies in Turkey. With its three EU-GMP accredited manufacturing facilities, approximately 2900 employees and state-of-the-art R&D centre DEVA targets to become a world-class player. Focusing on developing innovative new forms and products of high added value, DEVA allocated approximately 7 % of its turnover to R&D in 2023.

Deva Holding completed year 2023 successfully closed te year ranking 3rd with  5.2% market share in term of boxes and 6th with 2.9% market share in TL, based on IQVIA data.
 

Comprehensive Product Portfolio

DEVA Holding has more than 650 products in 14 therapeutic areas including oncology, ophthalmology and respiratory system products among others. DEVA Holding has been creating difference by releasing new products into market each year consistently.

Manufacturing Capabilities

DEVA's manufacturing capacity allows production of different pharmaceutical forms at large scales:

Non-sterile                                                     

• Tablets
• Coated Tablets
• Enteric – Coated Tablets
• Bilayer Tablets
• Chewable tablets
• Capsules
• Micropellet Capsules
• Softgel Capsules
• Sugar Coated Pills
• Syrups
• Suspensions
• Creams
• Pomades
• Ointments
• Drops
• Sprays
• Gels
• Suppositories
• MDI (Metered Dose Inhaler)
• DPI (Dry Powder Inhaler)

Sterile

• Ampoules
• Vial
• Lyophilized Vial
• Eye drop & Nebul
• Sterile Animal Health

Established Quality Standards

The high quality of DEVA production facilities are endorsed by globally recognized certification bodies:

•  EU – GMP (German Health Authority - Baden Württemberg, Portuguese Health Authority - Infarmed)
•  FDA (U.S. Food and Drug Administration)
•  MedSafe (New Zealand Medicines and Medical Devices Safety Authority)
•  ISO 9001 Quality Management System
•  ISO 27001 Information Security Management System
•  ISO 14001 Environmental Management System
•  BS OHSAS 18001 Occupational Health and Safety Management

Manufacturing Facilities

DEVA has three manufacturing facilities which are endorsed by internationally recognized certifications proving the high quality standards of DEVA.